Statements (98)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:activities |
mimics natural insulin secretion
|
| gptkbp:appointed_by |
gptkb:superhero
inhalation powder |
| gptkbp:approves |
gptkb:2014
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:clinical_trial |
Phase 3
conducted for efficacy mealtime insulin AFREZZA® in Type 1 Diabetes AFREZZA® in Type 2 Diabetes Phase 3 completed as needed with meals |
| gptkbp:competitors |
other rapid-acting insulins
|
| gptkbp:contraindication |
gptkb:healthcare_organization
chronic lung disease |
| gptkbp:demographics |
varies widely
|
| gptkbp:dosage_form |
gptkb:printer
gptkb:superhero |
| gptkbp:duration |
2-3 hours
|
| gptkbp:education |
inhalation technique
inhalation technique required |
| gptkbp:effective_date |
January 2014
|
| gptkbp:feedback |
mixed reviews
mixed reviews on ease of use |
| gptkbp:formulation |
inhaled insulin
powder for inhalation dry powder |
| gptkbp:has_ability |
4 units, 8 units, 12 units
|
| gptkbp:healthcare |
important for prescribing
|
| https://www.w3.org/2000/01/rdf-schema#label |
Afrezza
|
| gptkbp:indication |
mealtime blood sugar control
|
| gptkbp:ingredients |
insulin human
|
| gptkbp:interacts_with |
other antidiabetic agents
with other diabetes medications |
| gptkbp:invention |
2024
patented |
| gptkbp:is_available_in |
3-unit cartridges
4-unit cartridges 8-unit cartridges |
| gptkbp:is_effective_against |
improves postprandial glucose control
|
| gptkbp:is_monitored_by |
blood glucose levels
|
| gptkbp:is_used_for |
gptkb:Company
treatment of diabetes |
| gptkbp:manager |
inhalation
|
| gptkbp:manufacturer |
gptkb:Mann_Kind_Corporation
|
| gptkbp:market |
gptkb:2015
|
| gptkbp:marketed_as |
gptkb:United_States
|
| gptkbp:marketing_strategy |
focus on convenience and lifestyle
|
| gptkbp:outcome |
still being studied
|
| gptkbp:packaging |
disposable inhaler
|
| gptkbp:pharmacokinetics |
rapid onset of action
rapid absorption insulin action |
| gptkbp:population |
adults with type 2 diabetes
adults and children over 4 adults with type 1 diabetes |
| gptkbp:premiered_on |
approximately 12-15 minutes
|
| gptkbp:price |
varies by pharmacy
higher than some injectable insulins |
| gptkbp:provides_information_on |
not first-line therapy
ADA Standards of Medical Care recommended for type 1 and type 2 diabetes |
| gptkbp:public_perception |
seen as innovative
|
| gptkbp:receives_funding_from |
supported by grants and partnerships
|
| gptkbp:regulatory_body |
gptkb:FDA
|
| gptkbp:regulatory_compliance |
approved for marketing
approved for use in adults initial approval process |
| gptkbp:requires |
gptkb:theorem
|
| gptkbp:research |
ongoing for long-term effects
|
| gptkbp:research_focus |
cost-effectiveness
patient adherence long-term safety efficacy in children comparison with other insulins quality of life impact |
| gptkbp:safety_features |
generally well tolerated
lung function tests |
| gptkbp:scholarships |
available through manufacturer
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
cough
hypoglycemia throat irritation cough, throat irritation lung function decline |
| gptkbp:storage |
room temperature
|
| gptkbp:suitable_for |
smokers
asthma patients COPD patients |
| gptkbp:supply_chain |
managed by Mann Kind Corporation
|
| gptkbp:treatment |
improved glycemic control
|
| gptkbp:type_of_care |
can be affected by inhalation method
|
| gptkbp:type_of_insurance |
varies by plan
may vary |
| gptkbp:bfsParent |
gptkb:Mann_Kind_Corporation
|
| gptkbp:bfsLayer |
5
|